Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8<sup>+</sup> T cell responses and promoting tertiary lymphoid structure formation.

Nature communications·2026
Same author

Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer.

International journal of clinical oncology·2026
Same author

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Targeted oncology·2026
Same author

Combination of CHK1 and CHK2 inhibitors exerts synergistic antitumor effects against neuroblastoma cells.

Pediatric research·2026
Same author

Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer Society.

International journal of clinical oncology·2026
Same author

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

Nature cancer·2026

Related Experiment Video

Updated: Jun 29, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.5K

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.

Hidetoshi Hayashi1, Kenji Chamoto2,3, Ryusuke Hatae2

  • 1Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

The Journal of Clinical Investigation
|April 1, 2024
PubMed
Summary
This summary is machine-generated.

High levels of soluble immune factors, including soluble PD-L1 and sCTLA-4, predict non-response to PD-1/PD-L1 blockade in non-small cell lung cancer patients with exhausted immunity.

Keywords:
ImmunotherapyLung cancerOncologyT cells

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

260

Related Experiment Videos

Last Updated: Jun 29, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.5K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

260

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Accurate patient stratification is crucial for effective PD-1/PD-L1 blockade therapy in non-small cell lung cancer (NSCLC).
  • Current biomarkers may not fully capture the complex immune landscape influencing treatment response.

Purpose of the Study:

  • To investigate soluble immune-checkpoint molecules as predictive biomarkers for PD-1/PD-L1 blockade in advanced NSCLC.
  • To identify combinations of soluble factors that can predict treatment response.

Main Methods:

  • Measured plasma levels of soluble PD-L1, PD-1, and CTLA-4 in NSCLC patients undergoing various treatments.
  • Utilized a prospective biomarker-finding trial and retrospective observational cohorts.
  • Employed a sensitive chemiluminescence-based assay for soluble immune-checkpoint molecule quantification.

Main Results:

  • Higher soluble immune factor concentrations correlated with non-responsiveness to PD-1/PD-L1 blockade in immune-reactive tumors.
  • This association was not observed with cytotoxic chemotherapy or targeted therapy.
  • Combined soluble PD-L1 (sPD-L1) and sCTLA-4 effectively differentiated responders from non-responders in immune-reactive tumors.

Conclusions:

  • Soluble immune factor combinations may identify NSCLC patients with terminal antitumor immunity exhaustion, unlikely to respond to PD-1/PD-L1 blockade.
  • These combinations, along with tumor PD-L1 (tPD-L1), show promise in predicting treatment response in NSCLC.